Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1991792 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $69.12Day −4.82%Mkt cap $6.1B1Y +165.4%Off 52W high −10.2%Vol (1Y) 58.2%
Daily closing price, split-adjusted to the current basis; 2.5y shown of 623 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest13.7% of sh out |
| Days to cover12.2d |
| 13F net flow (QoQ)+7.22% |
| Top-10 13F concentration53.2% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$5.1M |
| Earnings (TTM)-$186.7M |
| ROE−21.7% |
| Net margin−3985.0% |
| Debt / equity0.00× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+66.5% |
| 1Y+165.4% |
| Since incept. (ann.)+28.1% |
Total return through 2026-07-29 · series begins 2024-01-25. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)58.2% |
| Ann. volatility (3Y)63.7% |
| Sharpe (1Y)2.01 |
| Sharpe (3Y)0.71 |
| Max drawdown (1Y)−27.4% |
| Max drawdown (3Y)−67.5% |
| Beta (3Y vs SPY)0.23 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 7.0M | $473M | 7.92% | +247.1% |
| T. Rowe Price Investment Management, Inc. | 6.7M | $455M | 7.62% | +1347.0% |
| Decheng Capital LLC | 6.4M | $431M | 7.22% | +0.0% |
| WELLINGTON MANAGEMENT GROUP LLP | 5.4M | $364M | 6.09% | −10.5% |
| BlackRock, Inc. | 5.1M | $343M | 5.74% | +4.6% |
| FMR LLC | 3.8M | $255M | 4.27% | −12.4% |
| TCG Crossover Management, LLC | 3.7M | $248M | 4.16% | +0.0% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.7M | $247M | 4.14% | +6.1% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 101.8% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 9,222,491 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-08 | −$0.71 | — | $1.1M | +1982.7% |
| 2025-12-31 | 2026-02-27 | — | — | $2.3M | +409.2% |
| 2025-09-30 | 2025-11-14 | −$0.57 | — | $1.7M | +3774.4% |
| 2025-06-30 | 2025-08-08 | −$0.54 | — | $0 | −100.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Commercial And Development Revenue 80% · License And Collaboration Revenue 20%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
